A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)
A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants
Merck Sharp & Dohme LLC
39 participants
Mar 18, 2026
INTERVENTIONAL
Conditions
Summary
Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF. The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.
Eligibility
Inclusion Criteria2
- Is in good health
- Has a body mass index (BMI) ≥18 and ≤32 kg/m\^2
Exclusion Criteria2
- Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
- Has a history of cancer (malignancy)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral administration
Oral administration
Oral administration
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07431866